Navigation Links
Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
Date:3/10/2009

pproach to patient treatment for schizophrenia by making it possible for the first time, to select a clinical dose capable of saturating 5HT2A receptors while permitting the "dialing in" of an optimal amount of dopamine receptor modulation by simple dose adjustments using a single drug. The ability to optimize the level of dopamine receptor modulation holds promise for the reduction of psychotic symptoms without incurring high levels of dopamine antagonism that cause motor disturbances and other deleterious side effects. In addition, the wide separation of affinity at 5HT2A and D2 receptors may allow for administration of the appropriate amount of dopamine modulation for antipsychotic maintenance therapy and the treatment of bipolar disorders.

ITI-007 has a low propensity to interact with receptors that mediate deleterious cardiovascular events, sedation and rapid and significant weight gain.

The present data show that ITI-007 is sleep promoting without having sedative properties and should not exhibit adverse effects during the night (e.g. falls, amnesia) or next day hangover effects that are commonly associated with other sleep medications. ITI-007 is expected to have a strong safety profile with no addiction liability. This compound is being evaluated for the treatment of sleep disorders in various patient populations with sleep maintenance problems and in other sleep disorders such as sleep disorders in depression, other mood disorders, Alzheimer's disease and schizophrenia.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide r
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
2. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
3. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
4. MaxCyte Introduces the GT(TM) Flow Transfection System for Application with Autologous and Allogeneic Stem Cell Therapies
5. GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C
6. Old and new therapies combine to tackle atherosclerosis
7. Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report
8. Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia
9. 18-Month Extension of Reimbursement Rates for Radioimmunotherapies Becomes Law After Congressional Override of Presidential Veto
10. Congress Extends 2007 Reimbursement Rates for Radioimmunotherapies for 18 Months
11. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 Strategic marketing and branding agency, ... name, Able&Co. , The agency was founded in 2008 ... its inception, continuing to expand its business each year. ... with a core focus on branding and marketing strategy. ... name and visual identity to reflect who we have ...
(Date:3/6/2015)... Global Specimen Solutions, Inc. ( http://www.globalspecimensolutions.com ... management and informatics, announced today that Series A ... is excited to catapult our growing momentum in ... enhance our proprietary informatics tools and infrastructure to ... has proved rapid market uptake of our clinical ...
(Date:3/6/2015)... , March 6, 2015   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... Company,s fourth quarter and full year 2014 financial results will ... the Company will host a conference call and live ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... veterans to be able to get an Advanced Semen ... money, stress, blaming and guessing are all risk factors ... assuming the woman is the source of the infertility. ... female. LifeCell Dx has the simplest, least complicated ...
Breaking Biology Technology:Red House Group Reveals New Identity as Able&Co. 2Global Specimen Solutions, Inc. Closes Series A Funding 2Global Specimen Solutions, Inc. Closes Series A Funding 3BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... MYL ) today announced that it has received ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... the generic version of Merck and Co.,s Singulair(R), which ... the 12 months ending March 31 for the same ...
... announced that it will present preliminary data from its Phase I ... the American Society of Clinical Oncologists (ASCO), in Orlando, Florida, USA.Dr ... be presenting the poster in the Develop m ... Vascula r ...
... May 28 The 500th patient was supported with ... as the,"Berlin Heart") since the first implantation of the ... device at the Children,s Memorial,Hospital in Chicago and has ... Alejandra had been diagnosed a few weeks ...
Cached Biology Technology:Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO 2500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device 2
(Date:2/5/2015)... Feb. 5, 2015  Marken is starting its 35 ... has launched a new marketing campaign to solidify its ... The new campaign focuses on First as ... shipments. The first headline in the series, ... priorities with its client,s priorities. Marken recognizes the need ...
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... website ( http://www.nxt-id.com/ ) as part of its 2015 ... The Company launched its new consumer website for Wocketwallet.com ... , CEO of NXT-ID said, "Our new corporate website ...
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
Breaking Biology News(10 mins):Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... the University of Sheffield and Queen Mary, University of ... damage by sunlight when they are faced with extreme ... Nature, could have implications both for adapting plants to ... better harness solar energy. Photosynthesis in plants ...
... fickle as wind itself, can be groomed to become ... a lower cost than at present, according to scientists ... wind farms throughout a given geographic area with transmission ... into one powerful energy source. The findings are ...
... studied and controversial ecogeographical patterns, and refers to the ... Although it has been studied since the mid 19th ... techniques have made it possible to disentangle the underlying ... study in the journal Ecography, an international team of ...
Cached Biology News:Scientists unravel plants' natural defenses 2The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 2The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 3The power of multiples: Connecting wind farms can make a more reliable - and cheaper - power source 4
... (Vesicle-Associated Membrane Protein 2, Synaptobrevin ... share homology with any other ... is expected that the antibody ... Macaca multata and bovine due ...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
Human GCP-2 is a member of the CXC family of chemokines. It also promotes neutrophil chemotaxis and deganulation. GF063 is an 8.0 kDa protein containing 73 amino acid residues....
Immunogen for A300-655A was a phosphorylated synthetic peptide, which represented a portion of human RNA Polymerase II (GeneID 5430) around serine 5 of the C-terminal repeat YSPTSPS....
Biology Products: